Search Results - "EJLERTSEN, Bent"

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis by Pedersen, Rikke Nørgaard, Esen, Buket Öztürk, Mellemkjær, Lene, Christiansen, Peer, Ejlertsen, Bent, Lash, Timothy Lee, Nørgaard, Mette, Cronin-Fenton, Deirdre

“…Abstract Background Extended, more effective breast cancer treatments have increased the prevalence of long-term survivors. We investigated the risk of late…”
Get full text

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial by Chan, Arlene, Prof, Delaloge, Suzette, MD, Holmes, Frankie A, MD, Moy, Beverly, MD, Iwata, Hiroji, MD, Harvey, Vernon J, MD, Robert, Nicholas J, MD, Silovski, Tajana, MD, Gokmen, Erhan, MD, von Minckwitz, Gunter, Prof, Ejlertsen, Bent, MD, Chia, Stephen K L, MD, Mansi, Janine, MD, Barrios, Carlos H, Prof, Gnant, Michael, Prof, Buyse, Marc, ScD, Gore, Ira, MD, Smith, John, MD, Harker, Graydon, MD, Masuda, Norikazu, MD, Petrakova, Katarina, MD, Zotano, Angel Guerrero, MD, Iannotti, Nicholas, MD, Rodriguez, Gladys, MD, Tassone, Pierfrancesco, Prof, Wong, Alvin, PharmD, Bryce, Richard, MBChB, Ye, Yining, PhD, Yao, Bin, MS, Martin, Miguel, Prof

“…Summary Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive…”
Get full text

Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status by Rossing, Maria, Pedersen, Christina Bligaard, Tvedskov, Tove, Vejborg, Ilse, Talman, Maj-Lis, Olsen, Lars Rønn, Kroman, Niels, Nielsen, Finn Cilius, Jensen, Maj-Britt, Ejlertsen, Bent

“…Axillary lymph node status is an important prognostic factor for breast cancer patients and sentinel lymph node biopsy (SLNB) is a less invasive surgical…”
Get full text

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial by Skriver, Signe Korsgaard, Jensen, Maj-Britt, Knoop, Ann Soegaard, Ejlertsen, Bent, Laenkholm, Anne-Vibeke

“…The presence of tumour-infiltrating lymphocytes (TILs) is associated with response to neoadjuvant chemotherapy among patients with triple-negative and…”
Get full text

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study by Borgquist, Signe, Giobbie-Hurder, Anita, Ahern, Thomas P, Garber, Judy E, Colleoni, Marco, Láng, István, Debled, Marc, Ejlertsen, Bent, von Moos, Roger, Smith, Ian, Coates, Alan S, Goldhirsch, Aron, Rabaglio, Manuela, Price, Karen N, Gelber, Richard D, Regan, Meredith M, Thürlimann, Beat

“…Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the…”
Get full text

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data by Leo, Angelo Di, Dr, Desmedt, Christine, PhD, Bartlett, John M S, Prof, Piette, Fanny, PhD, Ejlertsen, Bent, MD, Pritchard, Kathleen I, Prof, Larsimont, Denis, MD, Poole, Christopher, Prof, Isola, Jorma, Prof, Earl, Helena, Prof, Mouridsen, Henning, MD, O'Malley, Frances P, MD, Cardoso, Fatima, MD, Tanner, Minna, MD, Munro, Alison, PhD, Twelves, Chris J, Prof, Sotiriou, Christos, MD, Shepherd, Lois, MD, Cameron, David, Prof, Piccart, Martine J, Prof, Buyse, Marc, PhD

“…Summary Background Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as…”
Get full text

Survival outcomes for HER2-low breast cancer: Danish national data by Sode, Michael, Nielsen, Kåre, Jensen, Maj-Britt, Berg, Tobias, Knoop, Ann, Ejlertsen, Bent, Lænkholm, Anne-Vibeke

“…Background and purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous…”
Get full text

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up by Regan, Meredith M, Dr, Neven, Patrick, MD, Giobbie-Hurder, Anita, MS, Goldhirsch, Aron, MD, Ejlertsen, Bent, MD, Mauriac, Louis, MD, Forbes, John F, FRACS, Smith, Ian, MD, Láng, István, MD, Wardley, Andrew, MD, Rabaglio, Manuela, MD, Price, Karen N, BS, Gelber, Richard D, PhD, Coates, Alan S, MD, Thürlimann, Beat, MD

“…Summary Background Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and…”
Get full text

Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial by Møller, Tom, Andersen, Christina, Lillelund, Christian, Bloomquist, Kira, Christensen, Karl Bang, Ejlertsen, Bent, Tuxen, Malgorzata, Oturai, Peter, Breitenstein, Ulla, Kolind, Cecilie, Travis, Pernille, Bjerg, Tina, Rørth, Mikael, Adamsen, Lis

“…Cardiorespiratory fitness is an independent risk factor for cardiovascular disease and shortened life expectancy in breast cancer survivors. This randomised…”
Get full text

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer by Jensen, Maj-Britt, Lænkholm, Anne-Vibeke, Nielsen, Torsten O, Eriksen, Jens Ole, Wehn, Pernille, Hood, Tressa, Ram, Namratha, Buckingham, Wesley, Ferree, Sean, Ejlertsen, Bent

“…The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the…”
Get full text

High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients by Nielsen, Kåre, Sode, Michael, Jensen, Maj-Britt, Berg, Tobias, Knoop, Ann, Ejlertsen, Bent, Laenkholm, Anne-Vibeke

“…Abstract Background Considering the recent advancements in the treatment of breast cancer with low expression of human epidermal growth factor receptor 2…”
Get full text

Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark by Hjorth, Cathrine Fonnesbech, Damkier, Per, Ejlertsen, Bent, Lash, Timothy, Sarensen, Henrik Toft, Cronin-Fenton, Deirdre

“…Abstract Background To investigate how socioeconomic position (SEP) influences the effectiveness of cancer-directed treatment in premenopausal breast cancer…”
Get full text

Correction: Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark by Hjorth, Cathrine Fonnesbech, Damkier, Per, Ejlertsen, Bent, Lash, Timothy, Sørensen, Henrik Toft, Cronin-Fenton, Deirdre

“…Fig. 2 figure 1 Incidence rates and incidence rate ratios of breast cancer recurrence by socioeconomic position. Abbreviations: CI, Confidence Interval; IR,…”
Get full text

A catalog of curated breast cancer genes by Bose, Muthiah, Benada, Jan, Thatte, Jayashree Vijay, Kinalis, Savvas, Ejlertsen, Bent, Nielsen, Finn Cilius, Sørensen, Claus Storgaard, Rossing, Maria

“…Purpose Decades of research have identified multiple genetic variants associated with breast cancer etiology. However, there is no database that archives…”
Get full text

High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial by Nielsen, Torsten O, Jensen, Maj-Brit, Burugu, Samantha, Gao, Dongxia, Jørgensen, Charlotte L Tykjaer, Balslev, Eva, Ejlertsen, Bent

“…Luminal A breast cancers have better prognosis than other molecular subtypes. Luminal A cancers may also be insensitive to adjuvant chemotherapy, although…”
Get full text

Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients by Woolpert, Kirsten M, Schmidt, Julie A, Ahern, Thomas P, Hjorth, Cathrine F, Farkas, Dóra K, Ejlertsen, Bent, Collin, Lindsay J, Lash, Timothy L, Cronin-Fenton, Deirdre P

“…Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is…”
Get full text

Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer by Jørgensen, Nanna, Hviid, Thomas Vauvert F., Nielsen, Lise B., Sønderstrup, Ida M. H., Eriksen, Jens Ole, Ejlertsen, Bent, Gerdes, Anne-Marie, Kruse, Torben A., Thomassen, Mads, Jensen, Maj-Britt, Lænkholm, Anne-Vibeke

“…Background The prognostic value of tumour-infiltrating lymphocytes (TILs) in breast cancer is well-established. However, the investigation of specific T-cell…”
Get full text

Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice by Berg, Tobias, Jensen, Maj-Britt, Rossing, Maria, Axelsen, Christian T, Kümler, Iben, Søndergaard, Lise, Vogsen, Marianne, Knoop, Ann S, Ejlertsen, Bent

“…Primary metastatic breast cancer (pMBC) accounts for 5-10% of annual breast cancers with a median survival of 3-4 years, varying among subtypes. In Denmark,…”
Get full text

A careful reassessment of anthracycline use in curable breast cancer by Hurvitz, Sara Alsterlind, McAndrew, Nicholas P., Bardia, Aditya, Press, Michael F., Pegram, Mark, Crown, John P., Fasching, Peter A., Ejlertsen, Bent, Yang, Eric H., Glaspy, John A., Slamon, Dennis J.

“…It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though…”
Get full text

First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG by Celik, Alan, Berg, Tobias, Nielsen, Lise Birk, Jensen, Maj-Britt, Ejlertsen, Bent, Knoop, Ann, Andersson, Michael

“…Purpose: Dual blockade with trastuzumab and pertuzumab in combination with chemotherapy is the recommended first-line therapy for human epidermal growth factor…”
Get full text